Navigation Links
Transcept Pharmaceuticals Submits New Drug Application for Intermezzo(R) for Treatment of Middle-of-the-Night Awakenings
Date:10/1/2008

expected to cause residual sedative effects the next morning if used in the middle of the night with less than eight hours of time remaining in bed. The rapidly absorbed, lower zolpidem dose used in Intermezzo(R) has been developed to treat middle of the night awakenings, to be taken as needed at the time they occur.

Intermezzo(R) (zolpidem tartrate sublingual lozenge) employs the proprietary Transcept Bimucoral(R) technology in a mint-flavored, sublingual lozenge formulated to dissolve under the tongue in approximately two minutes. A bioavailability study has demonstrated that, despite the fact that Intermezzo(R) 3.5 mg contains only about one-third the dose of zolpidem as compared to an Ambien(R) 10 mg tablet, Intermezzo(R) achieved significantly higher overall bioavailability in the first 10 to 20 minutes after administration when compared to the higher Ambien(R) dose.

About the Proposed Transcept and Novacea Merger

On September 2, 2008, Transcept Pharmaceuticals, Inc. and Novacea, Inc. (Nasdaq: NOVC) entered into a definitive merger agreement under which Novacea will merge with Transcept in an all-stock transaction. Further information on the merger agreement is available in the last section of this press release, entitled "Additional Information about the Merger and Where to Find It."

About Transcept Pharmaceuticals

Transcept Pharmaceuticals is a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the fields of psychiatry and sleep medicine. The lead Transcept product candidate, Intermezzo(R), is a sublingual low dose formulation of zolpidem that has been developed for use as-needed for the treatment of insomn
'/>"/>

SOURCE Transcept Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Transcept Pharmaceuticals Announces Intent to Submit New Drug Application for Intermezzo(R) in Third Quarter 2008
2. Critical Pharmaceuticals Enter Sustained Release hGH Arena
3. Anadys Pharmaceuticals to Present at the JMP Securities Healthcare Focus Conference
4. Potentia Pharmaceuticals Announces Positive Safety Data and Study Expansion in Phase I Trial for Lead Drug Candidate POT-4
5. Quark Pharmaceuticals Announces First RNAi Drug Candidate Having a Novel, Proprietary Structure Covered by Quark Intellectual Property
6. Lotus Pharmaceuticals, Inc.s New Drug Laevo-Bambutero Begins Evaluation for Clinical Trials
7. VIA Pharmaceuticals Completes Patient Visits in Phase 2 Acute Coronary Syndrome (ACS) Trial
8. QuatRx Pharmaceuticals Announces Additional Data From Phase 3 Study for Ophena(TM) (Ospemifene Tablets) Showing Improvements in Clinical Symptoms of Vulvovaginal Atrophy
9. Anadys Pharmaceuticals Announces Successful Outcome of ANA598 Healthy Volunteer Study and Finalization of Study Design for Phase Ib Trial in HCV Patients
10. Oramed Pharmaceuticals Commences Phase 2A Trials of its Oral Insulin Capsule on Type 1 Diabetics
11. Vion Pharmaceuticals Enters into Agreement to Conduct a Phase I/II Clinical Trial of Cloretazine(R) in Combination with Induction Therapy in Poor Prognosis AML Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... 29, 2014  United Therapeutics Corporation (NASDAQ: ... for the District of New Jersey ... case against Sandoz, Inc. regarding United Therapeutics, Remodulin ® ... ruled that U.S. Patent No. 6,765,117 is both valid ... marketing its generic product until the expiration of that ...
(Date:8/29/2014)... -- Diseases largely eradicated in the United ... was declared eliminated in 2000, yet the CDC reports ... highest incidence in 20 years. In July, ... a problem of "epidemic proportions." ... these preventable diseases—in part because some parents (more than ...
(Date:8/29/2014)... DUBLIN , Aug. 29, 2014 ... the "Global Multiple Sclerosis Drugs Market 2014-2018" ... is a chronic, inflammatory medical condition that results in ... damaged because of an abnormal response by the immune ... (CNS). It is a potentially debilitating disease in which ...
Breaking Medicine Technology:District Court Decision Received In Remodulin Patent Case 2Vaccines at the Crossroads: Outbreaks On the Rise Across America 2Vaccines at the Crossroads: Outbreaks On the Rise Across America 3Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 2Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 3
... Ala., Dec. 14 BioCryst,Pharmaceuticals, Inc. (Nasdaq: ... data evaluating forodesine HCl, the Company,s lead anti-cancer,compound, ... and lymphomas., Madeline Duvic, M.D., Deputy Chair, ... presented interim data from the Phase,I/II clinical study ...
... the Treatment of PKU, NOVATO, Calif., Dec. ... announced today that the U.S.,Food and Drug Administration ... Tablets, the first specific drug,therapy approved for the ... will commence tomorrow, and BioMarin will begin,promotion of ...
Cached Medicine Technology:Data Presented at 2007 ASH Meeting Demonstrate Activity of Forodesine HCl as a Single Agent or in Combination With Bendamustine in Certain Types of Leukemia and Lymphoma 2Data Presented at 2007 ASH Meeting Demonstrate Activity of Forodesine HCl as a Single Agent or in Combination With Bendamustine in Certain Types of Leukemia and Lymphoma 3Data Presented at 2007 ASH Meeting Demonstrate Activity of Forodesine HCl as a Single Agent or in Combination With Bendamustine in Certain Types of Leukemia and Lymphoma 4BioMarin Announces FDA Approval for Kuvan 2BioMarin Announces FDA Approval for Kuvan 3BioMarin Announces FDA Approval for Kuvan 4BioMarin Announces FDA Approval for Kuvan 5BioMarin Announces FDA Approval for Kuvan 6BioMarin Announces FDA Approval for Kuvan 7BioMarin Announces FDA Approval for Kuvan 8
(Date:8/29/2014)... a systematic review of clinical trials based on ... researchers have concluded that more trials are needed ... for postsurgical pain on a regular basis., Dr. ... pain research in the Department of Anesthesiology, and ... to determine whether the use of antidepressants for ...
(Date:8/29/2014)... Colo. (Sept. 2, 2014) A team of scientists ... reported the breakthrough discovery of a process to expand ... These findings could have implications that extend beyond cancer, ... autoimmune diseases., In an article published Aug. ... Charles C. Gates Center for Regenerative Medicine and Stem ...
(Date:8/29/2014)... Mass. (August 29, 2014, 2 PM US Eastern ... is to inject antibodies, commonly produced in animals, ... challenges ranging from safety to difficulties in developing, ... , New research led by Charles Shoemaker, ... and Global Health at the Cummings School of ...
(Date:8/29/2014)... EDMONTON, AB A new study from the research group ... AB) and the Lawson Health Research Institute (London, ON) has ... of cancer. The study, published in Cell Reports , ... spread of cancer entirely. , Roughly 2 in 5 ... four of them will die of the disease. In 2014, ...
(Date:8/29/2014)... Francisco, CA (PRWEB) August 30, 2014 ... 10 best web conference providers in the online service ... the list were global leaders Webex, GotoMeeting and Infinite. ... the industry users have to determine which provider is ... Essentially, web conference businesses search for compelling consumer goods ...
Breaking Medicine News(10 mins):Health News:Antidepressants show potential for postoperative pain 2Health News:CU scientists' discovery could lead to new cancer treatment 2Health News:Mice study shows efficacy of new gene therapy approach for toxin exposures 2Health News:Preventing cancer from forming 'tentacles' stops dangerous spread 2Health News:Top10InAction Reveals Best Web Conference Providers 2
... WASHINGTON, Sept. 2 Speaker Nancy Pelosi and Senate Majority Leader Harry Reid ... Session of Congress on Wednesday, September 9, 2009. , , ... , September 2, 2009 , , President Barack ... Dear Mr. President: , , Our nation is closer than ever ...
... ATLANTA, Sept. 2 /PRNewswire-FirstCall/ -- Gentiva Health Services, Inc. ... health services, announced today that it has completed its acquisition of ... the Rush Health System, located in central Mississippi and west central ... , "We extend a warm welcome to all ...
... , , WASHINGTON, Sept. ... President, Campaign for Tobacco-Free Kids: , , (Logo: ... have taken decisive action to protect the state,s kids and taxpayers from ... by $1 to $3.00 per pack, making it the second highest state ...
... Study found more than half of advanced basal cell carcinomas ... -- An experimental cancer drug that switches off the so-called ... patients with advanced basal cell carcinoma, a type of skin ... from medulloblastoma, the most common form of brain cancer in ...
... , OAKLAND, Calif., Sept. 2 Wigix ( ... database on the web. Wigix has surpassed Overstock.com and ... (Source: Internet Retailers Top 500 Guide 2009 Edition) , , ... thousand SKUs during its public beta launch in June 2007. This milestone marks ...
... , , , ... the House Democrat healthcare bill (H.R. 3200) that violate President Obama,s promise ... $250,000 per year. The White House has told reporters that Obama ... week, which begs the question: , , ...
Cached Medicine News:Health News:Gentiva(R) Health Services Completes Acquisition of Home Health Agency 2Health News:Gentiva(R) Health Services Completes Acquisition of Home Health Agency 3Health News:Connecticut Cigarette Tax Increase Delivers Victory for Kids and Taxpayers; $1 Increase Gives State Second Highest Cigarette Tax in the Nation 2Health News:Connecticut Cigarette Tax Increase Delivers Victory for Kids and Taxpayers; $1 Increase Gives State Second Highest Cigarette Tax in the Nation 3Health News:New Compound Shrinks Skin Cancers 2Health News:New Compound Shrinks Skin Cancers 3Health News:New Compound Shrinks Skin Cancers 4Health News:Wigix Announces 1 Million in Open Sell Orders 2Health News:Obama's 'Specific' Healthcare Speech: Will He Disavow Pledge-Breaking Tax Hikes in House Dem Health Bill? 2
Stainless steel construction to withstand sterilization modalities (EtO) Wide angle of view...
Inquire...
ENDOlap™ laparoscopes provide excellent image linearity and flatness of field....
The Fujinon's R410 laparoscope is the first to bring a 410,000 pixel CCD to the end of the scope. Superior imaging and color replication, along with a unique lens washing capability make the R410 the...
Medicine Products: